Company Profiles

driven by the PitchBook Platform

ViaCyte

Description

Developer of cell and drug therapies to treat diabetes and other chronic diseases. The company develops human embryonic stem cells for Type 1 and Type 2 diabetic patients, as well as therapies based on pancreatic beta cell progenitors derived from human pluripotent stem cells. It develops insulin-producing cells from human embryonic stem cells to produce islet cells and Encaptra, a vascularizing device that enables implanted pancreatic progenitor cells to survive and differentiate into functioning islet cells.

1999

Founded

PRIVATE

Status

51-200

Employees

Grant

Latest Deal Type

$16.6M

Latest Deal Amount

$130M

Total Amount Raised

Description

Developer of cell and drug therapies to treat diabetes and other chronic diseases. The company develops human embryonic stem cells for Type 1 and Type 2 diabetic patients, as well as therapies based on pancreatic beta cell progenitors derived from human pluripotent stem cells. It develops insulin-producing cells from human embryonic stem cells to produce islet cells and Encaptra, a vascularizing device that enables implanted pancreatic progenitor cells to survive and differentiate into functioning islet cells.

Website:

www.viacyte.com

Formerly Known As

Novocell

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Delivery
Other Pharmaceuticals and Biotechnology

Primary Office

3550 General Atomics Court San Diego, CA 92121United States +1 (858) 455-3708
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore ViaCyte's full profile, request a free trial.

ViaCyte Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

ViaCyte Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

ViaCyte Investors (13)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Alloy VenturesVenture CapitalMinority000 0000000 0000
AMA98 venturesLimited PartnerMinority000 0000000 0000
Asset Management VenturesVenture CapitalMinority000 0000000 0000
BD VenturesCorporate Venture CapitalMinority000 0000000 0000
Bresa Gen 1OtherMinority000 0000000 0000
Alloy Ventures Venture Capital
AMA98 ventures Limited Partner
Asset Management Ventures Venture Capital
BD Ventures Corporate Venture Capital
Bresa Gen 1 Other

ViaCyte Executive Team (7)

NameTitleBoard
Seat
Contact
Info
Paul Laikind Ph.DChief Executive Officer, President & Board Member
Michael Scott Ph.DVice President, Device Research & Development & Chief Development Officer
Kevin D'Amour Ph.DVice President, Research & Chief Scientific Officer
Anne SandanVice President, Finance & Corporate Controller, Treasurer/Secretary
Allan Robins Ph.DSenior Vice President, Science & Technology
Paul Laikind Ph.D Chief Executive Officer, President & Board Member
Michael Scott Ph.D Vice President, Device Research & Development & Chief Development Officer
Kevin D'Amour Ph.D Vice President, Research & Chief Scientific Officer
Anne Sandan Vice President, Finance & Corporate Controller, Treasurer/Secretary
Allan Robins Ph.D Senior Vice President, Science & Technology

ViaCyte Board Members (8)

NameRepresentingRoleSinceContact
Info
Asish Xavier Ph.DSelfBoard Member000 0000
Donald ElmerPacific Horizon VenturesFounder & Managing General Partner000 0000
Franklin Johnson Jr.Asset Management VenturesFounder000 0000
Fred MiddletonSanderling VenturesManaging Director000 0000
Mark FolettaSelfBoard Member000 0000
Asish Xavier Ph.D Board Member Self
Donald Elmer Founder & Managing General Partner Pacific Horizon Ventures
Franklin Johnson Jr. Founder Asset Management Ventures
Fred Middleton Managing Director Sanderling Ventures
Mark Foletta Board Member Self
Request full access to PitchBook